President Trump’s prescription drug pricing plan has a lot that biopharma manufacturers are unhappy about but there are some positive themes in the mix, including possible restrictions to the 340B drug discount program.
The wide-ranging blueprint for lowering prices contemplates several revisions to the Medicare Part D program that has manufacturers particularly worried
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?